These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
261 related items for PubMed ID: 28646336
21. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA, Murray BM, Barres B, Tessier-Lavigne M, Bernard CC. Nat Neurosci; 2004 Jul; 7(7):736-44. PubMed ID: 15184901 [Abstract] [Full Text] [Related]
24. IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation. Psachoulia K, Chamberlain KA, Heo D, Davis SE, Paskus JD, Nanescu SE, Dupree JL, Wynn TA, Huang JK. Brain; 2016 Dec; 139(Pt 12):3121-3136. PubMed ID: 27797811 [Abstract] [Full Text] [Related]
25. Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord. Kataria H, Alizadeh A, Shahriary GM, Saboktakin Rizi S, Henrie R, Santhosh KT, Thliveris JA, Karimi-Abdolrezaee S. Glia; 2018 Mar; 66(3):538-561. PubMed ID: 29148104 [Abstract] [Full Text] [Related]
26. Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS? Kim MJ, Kang JH, Theotokis P, Grigoriadis N, Petratos S. Cells; 2018 Dec 20; 8(1):. PubMed ID: 30577457 [Abstract] [Full Text] [Related]
27. The role of Nogo-A in axonal plasticity, regrowth and repair. Pernet V, Schwab ME. Cell Tissue Res; 2012 Jul 20; 349(1):97-104. PubMed ID: 22588543 [Abstract] [Full Text] [Related]
29. Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration. Kalafatakis I, Papagianni F, Theodorakis K, Karagogeos D. Int J Mol Sci; 2023 Feb 24; 24(5):. PubMed ID: 36901909 [Abstract] [Full Text] [Related]
31. E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord. Church JS, Milich LM, Lerch JK, Popovich PG, McTigue DM. Glia; 2017 Jun 24; 65(6):883-899. PubMed ID: 28251686 [Abstract] [Full Text] [Related]
32. Therapeutic DNA vaccination as a repair strategy following spinal cord injury. Kou SB, Xu G, Jiang XD, Xu RX, Tang YP, Xu G, Cai YQ, Du MX, Xiao ZC. Cell Mol Neurobiol; 2010 Mar 24; 30(2):275-82. PubMed ID: 19757023 [Abstract] [Full Text] [Related]
33. Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration. Xu G, Nie DY, Chen JT, Wang CY, Yu FG, Sun L, Luo XG, Ahmed S, David S, Xiao ZC. J Neurochem; 2004 Nov 24; 91(4):1018-23. PubMed ID: 15525355 [Abstract] [Full Text] [Related]
34. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Huizinga R, Gerritsen W, Heijmans N, Amor S. Neurobiol Dis; 2008 Dec 24; 32(3):461-70. PubMed ID: 18804534 [Abstract] [Full Text] [Related]
38. Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis. Warford JR, Lamport AC, Clements DR, Malone A, Kennedy BE, Kim Y, Gujar SA, Hoskin DW, Easton AS. Acta Neuropathol Commun; 2018 Jan 04; 6(1):4. PubMed ID: 29301568 [Abstract] [Full Text] [Related]
39. DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis. Bourquin C, van der Haar ME, Anz D, Sandholzer N, Neumaier I, Endres S, Skerra A, Schwab ME, Linington C. Eur J Pharmacol; 2008 Jun 24; 588(1):99-105. PubMed ID: 18495110 [Abstract] [Full Text] [Related]